The FDA will ask drug companies to follow late-stage clinical trial participants for a median of at least 2 months, starting after they receive a second dose of the vaccine, the newspaper reported. The FDA will also look for at least five cases of severe COVID-19 in the placebo group for each clinical trial, as well as cases in older patients.